西藏药业(600211.SH)：上半年净利润同比下降8.96% 拟10股派8.81元

Core Viewpoint - Xizang Pharmaceutical (600211.SH) reported a mixed performance in its semi-annual report, with a slight increase in revenue but a decline in net profit [1] Financial Performance - The company achieved operating revenue of 1,650.71 million yuan, representing a year-on-year growth of 2.23% [1] - The net profit attributable to shareholders decreased by 8.96% to 567.32 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 542.84 million yuan, showing a year-on-year increase of 3.69% [1] Product Sales - Sales revenue from the main product, Xinhuasu, was 1,455.73 million yuan, reflecting a year-on-year growth of 0.41% [1] - Revenue from other products reached 191.69 million yuan, marking a significant year-on-year increase of 18.83% [1] Dividend Distribution - The company announced a cash dividend of 8.81 yuan per 10 shares to all shareholders [1]